Alzheimer’s

CT scans of the brain
#Alzheimer's #Antibodies #Biogen #Biologics #Eisai #Neurodegenerative disorders

Data demonstrate long-term effect of lecanemab in early Alzheimer’s

Lecanemab-irmb (Leqembi), an anti-amyloid beta (Aβ) protofibril antibody, continues to show benefit for early Alzheimer’s disease (AD) patients over three years, according to new trial results. Eisai and Biogen shared the latest findings at the Alzheimer’s Association International Conference (AAIC) 2024, held in Philadelphia. Read More

#News

#Alpha Cognition #Alzheimer's #Drug delivery #FDA #Neurodegenerative disorders

US regulator approves galantamine prodrug for Alzheimer’s

The US Food and Drug Administration (FDA) has granted approval for Alpha Cognition’s Zunveyl (benzgalantamine) previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer’s disease (AD). Tolerability affects therapy adherence, with data showing that 55% of AD patients discontinue their medication after one year, mainly… Read More

#News #Regulatory

Jigsaw puzzle of the brain
#Alzheimer's #Dementia #Diabetes #GLP-1 #Novo Nordisk #Phase II trial #Weight loss

GLP-1 receptor agonist slows Alzheimer’s cognitive decline

In new revelations about glucagon-like peptide-1 (GLP-1) drugs like Ozempic, a study has demonstrated the therapies could protect against dementia. In a Phase IIb trial, Novo Nordisk’s GLP-1 receptor agonist liraglutide appears to reduce shrinking in the parts of the brain that control memory, learning, language… Read More

#News #Trending News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Eli Lilly #FDA #Neurodegenerative disorders #Phase III trial

FDA approves second anti-amyloid beta antibody for Alzheimer’s

Eli Lilly’s anti-amyloid beta monoclonal antibody (mAb) Kisunla (donanemab) has become the second disease-modifying therapy for Alzheimer’s disease (AD) to reach the US market, following approval by the US Food and Drug Administration (FDA). It has been approved by the regulator for the treatment of patients… Read More

#News #Regulatory #Trending News

Neurons
#Alzheimer's #Neurodegenerative disorders #Phase II trial #Regenerative Medicine #Spinogenix

Synapse-regenerating drug could reverse decline in Alzheimer’s

Spinogenix has initiated a Phase II trial to evaluate SPG302 for the treatment of adult participants with mild-to-moderate Alzheimer’s disease (AD), following approval for the trail in Australia. The study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of SPG302 in adult AD participants. Read More

#News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Funding #Neurodegenerative disorders #Private investment #University of Texas

$20 million donation supports neurodegeneration research

The University of Texas MD Anderson Cancer Center has been awarded $20 million to strengthen neurodegeneration research. The donation was awarded to the Belfer Neurodegeneration Consortium (BNDC), which aims to develop five new medicines for Alzheimer’s disease and related disorders over the next 10 years, with… Read More

#News

#Alzheimer's #Antibodies #Monoclonal antibodies #Neurodegenerative disorders #Therapeutic Antibodies

Therapeutic antibodies in the fight against Alzheimer’s

ImmunoBrain Checkpoint (IBC) is currently dosing patients in a clinical trial with its monoclonal antibody for Alzheimer’s disease (AD). DDW’s Megan Thomas caught up with Professor Michal Schwartz to learn more about her work and the work being carried out by IBC. MT: Can you provide an… Read More

#Exclusive Content

#Alzheimer's #Amyotrophic lateral sclerosis (ALS) #Autism #Neurodegenerative disorders #Neuroscience #Parkinson's

New DDW Highlights podcast: 18 March 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Following the recent AD/PD 2024 conference, which took place on 5-9 March in Lisbon,… Read More

#News

#Alzheimer's #Amyotrophic lateral sclerosis (ALS) #Autism #Neurodegenerative disorders #Neuroscience #Parkinson's

This week in drug discovery (11-15 March) 

News round-up for 11-15 March by DDW Digital Content Editor Diana Spencer. Following the recent AD/PD 2024 conference, which took place on 5-9 March in Lisbon, Portugal, there have been a number of key announcements regarding investigational therapies for neurological disorders, particularly Alzheimer’s disease and Parkinson’s disease. Read More

#News

CT scans of the brain
#Alzheimer's #Galimedix Therapeutics #Neurodegenerative disorders #Neuroscience #Preclinical investigations

New drug shows promising neuroprotective effects

Galimedix Therapeutics has announced data showing small molecule GAL-201 has neuroprotective and symptomatic alleviation potential in models of Alzheimer’s disease (AD). These new findings support previous studies where GAL-201 was characterised as a promising development candidate for the treatment of AD (Russ et. al. 2022). Read More

#News #Trending News

Dementia
#Alzheimer's #Eli Lilly #FDA #Neurodegenerative disorders #Phase III trial

FDA advisory committee meeting delays approval of donanemab

The US Food and Drug Administration (FDA) has revealed plans to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) to discuss the Phase III TRAILBLAZER-ALZ 2 trial. The trial evaluated the efficacy and safety of Eli Lilly’s donanemab in early… Read More

#News #Regulatory

Tau proteins
#Alzheimer's #Gene therapy #Preclinical investigations #Tau protein #Voyager Therapeutics

New data validates tau silencing gene therapy for Alzheimer’s

Voyager Therapeutics has announced new data from its two preclinical programmes targeting pathological tau for the treatment of Alzheimer’s disease. Data on VY-TAU01, Voyager’s lead anti-tau antibody candidate, and on Voyager’s tau silencing gene therapy programme will be presented at the upcoming 2024 International Conference on Alzheimer’s and… Read More

#Editor's Choice #News

Neurones in the brain
#Alzheimer's #Gene editing #Neurodegenerative disorders #Neuroscience

Advances in neuroscience drug discovery

Listen to this article on the DDW Podcast: Lu Rahman looks at neuroscience drug discovery – advances and challenges – and how breakthroughs in this field are helping address areas of unmet need.  Recent advances in biomarkers, research into the central nervous system and breakthroughs in… Read More

#Exclusive Content

#Alzheimer's #Cell therapy #Natural killer cells #Neurodegenerative disorders #NKGen #Phase I trial

The killer instinct: Using natural killer therapy to treat Alzheimer’s

DDW Editor Reece Armstrong speaks to Dr Paul Song, MD, NKGen and Dr Vince DeOrchis, clinician, to find out more about the investigational natural killer therapy SNK01 and the benefit of using a patient’s own cells to treat Alzheimer’s. In October 2023, pharmaceutical company NKGen Biotech… Read More

#Exclusive Content

Neuroscience innovation
#AI #Alzheimer's #Artificial intelligence (AI) #Biomarkers #Brain disease #Drug discovery #Inherited tauopathies #Mental health #Nervous system disorders #Neurodegenerative disorders #Neurology #Neuroscience #Neurotechnology #Psychiatry #Tau protein

New podcast on innovation in neuroscience

This is the latest episode of the free DDW narrated podcast, titled “Where is the latest innovation in neuroscience?” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Taking a new approach to tackle neurodegenerative diseases,… Read More

#News

#Alzheimer's #Cancer research #Cell therapy #CRISPR #Drug discovery #Parkinson's #Plant-based #Stem cells

New DDW Highlights podcast: 4 December 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The key drug discovery news this week focuses on experimental approaches to… Read More

#News